ciprofloxacin has been researched along with Bronchiectasis in 38 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
Bronchiectasis: Persistent abnormal dilatation of the bronchi.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We evaluated the efficacy and safety of ciprofloxacin dry powder for inhalation (DPI) in patients with non-cystic fibrosis bronchiectasis, two or more exacerbations in the previous year and predefined sputum bacteria." | 9.27 | RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis. ( Aksamit, T; Bandel, TJ; Criollo, M; De Soyza, A; Elborn, JS; Operschall, E; Polverino, E; Roth, K; Wilson, R; Winthrop, KL, 2018) |
| "Ciprofloxacin dry powder for inhalation (Ciprofloxacin DPI) is in development as long-term intermittent therapy to reduce the frequency of acute exacerbations in non-cystic fibrosis bronchiectasis (NCFB) patients with respiratory bacterial pathogens." | 9.24 | Ciprofloxacin Dry Powder for Inhalation in Patients with Non-Cystic Fibrosis Bronchiectasis or Chronic Obstructive Pulmonary Disease, and in Healthy Volunteers. ( Kappeler, D; Kietzig, C; Nagelschmitz, J; Sommerer, K; Stass, H; Weimann, B, 2017) |
| "Phase II, 24-week Australian/New Zealand multicentre, randomised, double-blind, placebo-controlled trial in 42 adult bronchiectasis subjects with ≥2 pulmonary exacerbations in the prior 12 months and ciprofloxacin-sensitive P aeruginosa at screening." | 9.17 | Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. ( Bilton, D; Bruinenberg, P; Cipolla, D; De Soyza, A; Gonda, I; Greville, HW; Kolbe, J; Serisier, DJ; Thompson, PJ, 2013) |
| "This phase II, randomised, double-blind, multicentre study (NCT00930982) investigated the safety and efficacy of ciprofloxacin dry powder for inhalation (DPI) in patients with non-cystic fibrosis bronchiectasis." | 9.17 | Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study. ( Alder, J; De Soyza, A; Greville, H; Hampel, B; O'Donnell, A; Polverino, E; Reimnitz, P; Welte, T; Wilson, R, 2013) |
| "This study tested the effect of adding inhaled tobramycin solution to oral ciprofloxacin (Cip) for the treatment of acute exacerbations of non-CF bronchiectasis in patients with P aeruginosa infection." | 9.12 | Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis. ( Bilton, D; Gotfried, M; Henig, N; Morrissey, B, 2006) |
| "The efficacy and safety of long-term ciprofloxacin therapy in the management of severe bronchiectasis were retrospectively assessed in patients who had taken oral ciprofloxacin continuously for at least 90 days." | 9.07 | Efficacy and safety of long-term ciprofloxacin in the management of severe bronchiectasis. ( Cole, PJ; Rayner, CF; Tillotson, G; Wilson, R, 1994) |
| "Five Spain(9V-3) Streptococcus pneumoniae strains were isolated from a patient with bronchiectasis who had received long-term ciprofloxacin therapy." | 7.72 | Genetic characterization of fluoroquinolone-resistant Streptococcus pneumoniae strains isolated during ciprofloxacin therapy from a patient with bronchiectasis. ( de la Campa, AG; Ferrandiz, MJ; Liñares, J; Manresa, F; Pallarés, R; Tubau, F, 2003) |
| "Ciprofloxacin (CIP) has poor lung targeting after oral inhalation." | 5.62 | Development of Inhalable Nanostructured Lipid Carriers for Ciprofloxacin for Noncystic Fibrosis Bronchiectasis Treatment. ( Aldosari, BN; Alfagih, IM; Aljunaidel, HA; Almarshidy, SS; Almurshedi, AS; Alquadeib, B; Eltahir, EKD; Mohamoud, AZ, 2021) |
| "Mannitol was added as a mucokinetic agent." | 5.51 | Novel Inhalable Ciprofloxacin Dry Powders for Bronchiectasis Therapy: Mannitol-Silk Fibroin Binary Microparticles with High-Payload and Improved Aerosolized Properties. ( Huang, Z; Jiang, J; Li, G; Lin, L; Liu, C; Lv, L; Quan, G; Wu, C; Wu, Q; Yu, X, 2019) |
| " Adverse events were recorded in only two patients and involved a slight elevation in liver function tests and eosinophilia." | 5.30 | The efficacy, safety and pharmacokinetics of intravenous ciprofloxacin in patients with lower respiratory tract infections. ( Hiraga, Y; Ohmichi, M, 1999) |
| "We evaluated the efficacy and safety of ciprofloxacin dry powder for inhalation (DPI) in patients with non-cystic fibrosis bronchiectasis, two or more exacerbations in the previous year and predefined sputum bacteria." | 5.27 | RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis. ( Aksamit, T; Bandel, TJ; Criollo, M; De Soyza, A; Elborn, JS; Operschall, E; Polverino, E; Roth, K; Wilson, R; Winthrop, KL, 2018) |
| "Ciprofloxacin dry powder for inhalation (Ciprofloxacin DPI) is in development as long-term intermittent therapy to reduce the frequency of acute exacerbations in non-cystic fibrosis bronchiectasis (NCFB) patients with respiratory bacterial pathogens." | 5.24 | Ciprofloxacin Dry Powder for Inhalation in Patients with Non-Cystic Fibrosis Bronchiectasis or Chronic Obstructive Pulmonary Disease, and in Healthy Volunteers. ( Kappeler, D; Kietzig, C; Nagelschmitz, J; Sommerer, K; Stass, H; Weimann, B, 2017) |
| "Phase II, 24-week Australian/New Zealand multicentre, randomised, double-blind, placebo-controlled trial in 42 adult bronchiectasis subjects with ≥2 pulmonary exacerbations in the prior 12 months and ciprofloxacin-sensitive P aeruginosa at screening." | 5.17 | Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. ( Bilton, D; Bruinenberg, P; Cipolla, D; De Soyza, A; Gonda, I; Greville, HW; Kolbe, J; Serisier, DJ; Thompson, PJ, 2013) |
| "This phase II, randomised, double-blind, multicentre study (NCT00930982) investigated the safety and efficacy of ciprofloxacin dry powder for inhalation (DPI) in patients with non-cystic fibrosis bronchiectasis." | 5.17 | Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study. ( Alder, J; De Soyza, A; Greville, H; Hampel, B; O'Donnell, A; Polverino, E; Reimnitz, P; Welte, T; Wilson, R, 2013) |
| "This study tested the effect of adding inhaled tobramycin solution to oral ciprofloxacin (Cip) for the treatment of acute exacerbations of non-CF bronchiectasis in patients with P aeruginosa infection." | 5.12 | Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis. ( Bilton, D; Gotfried, M; Henig, N; Morrissey, B, 2006) |
| "To examine the pharmacokinetics of ciprofloxacin and fleroxacin in plasma and sputum of patients with an acute exacerbation of chronic bronchitis or bronchiectasis following the first dose and again during the third day of treatment." | 5.09 | The pharmacokinetics of oral fleroxacin and ciprofloxacin in plasma and sputum during acute and chronic dosing. ( Begg, EJ; Buttimore, RC; Graham, GG; Neill, AM; Robson, RA; Saunders, DA; Town, GI, 2000) |
| "The efficacy of ciprofloxacin was studied in the treatment of 22 patients with hospital infection of the lower respiratory tract: 10 patients with nosocomial pneumonia, 8 with exacerbation of chronic obstructive bronchitis, 3 with exacerbation of mucoviscidosis and 1 with bronchiectasis." | 5.08 | [Effectiveness of ciprofloxacin in the treatment of hospital infections of the lower respiratory tract]. ( Avdeev, SN; Belevskiĭ, AS; Chuchalin, AG; Novikov, IuK, 1997) |
| "The efficacy and safety of long-term ciprofloxacin therapy in the management of severe bronchiectasis were retrospectively assessed in patients who had taken oral ciprofloxacin continuously for at least 90 days." | 5.07 | Efficacy and safety of long-term ciprofloxacin in the management of severe bronchiectasis. ( Cole, PJ; Rayner, CF; Tillotson, G; Wilson, R, 1994) |
| "A total of 150 patients with COPD, non-CF bronchiectasis or asthma, and P." | 3.11 | Targeted AntiBiotics for Chronic pulmonary diseases (TARGET ABC): can targeted antibiotic therapy improve the prognosis of Pseudomonas aeruginosa-infected patients with chronic pulmonary obstructive disease, non-cystic fibrosis bronchiectasis, and asthma? ( Alispahic, IA; Andreassen, HF; Armbruster, K; Bangsborg, J; Bodtger, U; Browatzki, A; Christensen, CW; Coia, JE; Datcu, R; Eklöf, J; Ellingsgaard, T; Fenlev, CS; Ghathian, KSA; Gundersen, L; Harboe, ZB; Heidemann, M; Janner, J; Jensen, JUS; Jensen, TT; Johansson, SL; Johnsen, S; Kjærgaard, JL; Lapperre, TS; Linde, H; Moberg, M; Nielsen, TL; Overgaard, RH; Pedersen, L; Rosenvinge, FS; Saeed, MI; Seersholm, N; Sivapalan, P; Sørensen, VM; Titlestad, I; Ulrik, CS; Vijdea, R; Weinreich, UM; Wilcke, T; Østergaard, C, 2022) |
| "Bronchiectasis is a chronic respiratory disease with heterogeneous etiology, characterized by a cycle of bacterial infection and inflammation, resulting in increasing airway damage." | 2.58 | Ciprofloxacin Dry Powder for Inhalation (ciprofloxacin DPI): Technical design and features of an efficient drug-device combination. ( Durbha, P; Elborn, JS; Haynes, A; McShane, PJ; Miller, DP; Mundry, T; Operschall, E; Tarara, TE; Weers, JG, 2018) |
| "Bronchiectasis is a chronic respiratory disease characterised by abnormal and irreversible dilatation of the smaller airways and associated with a mortality rate greater than twice that of the general population." | 2.58 | Dual antibiotics for bronchiectasis. ( Armstrong, R; Felix, LM; Grundy, S; Harrison, H; Lynes, D; Milan, SJ; Spencer, S, 2018) |
| "Ciprofloxacin (CIP) has poor lung targeting after oral inhalation." | 1.62 | Development of Inhalable Nanostructured Lipid Carriers for Ciprofloxacin for Noncystic Fibrosis Bronchiectasis Treatment. ( Aldosari, BN; Alfagih, IM; Aljunaidel, HA; Almarshidy, SS; Almurshedi, AS; Alquadeib, B; Eltahir, EKD; Mohamoud, AZ, 2021) |
| " Therefore, the optimal dosing of the CIP-(DXT-PAP) nanoplex must be carefully determined." | 1.56 | Ternary nanoparticle complex of antibiotic, polyelectrolyte, and mucolytic enzyme as a potential antibiotic delivery system in bronchiectasis therapy. ( Hadinoto, K; Tran, TT, 2020) |
| "d-Mannitol and l-leucine were used as the drying adjuvant and aerosol dispersion enhancer, respectively." | 1.43 | Dry powder inhaler formulation of high-payload antibiotic nanoparticle complex intended for bronchiectasis therapy: Spray drying versus spray freeze drying preparation. ( Chew, JW; Hadinoto, K; Teo, J; Yu, H, 2016) |
| "Moxifloxacin has unique side chains at positions 7 and 8 on its bicyclic ring structure." | 1.36 | Immediate hypersensitivity to moxifloxacin with tolerance to ciprofloxacin: report of three cases and review of the literature. ( Chang, B; Knowles, SR; Weber, E, 2010) |
| " Adverse events were recorded in only two patients and involved a slight elevation in liver function tests and eosinophilia." | 1.30 | The efficacy, safety and pharmacokinetics of intravenous ciprofloxacin in patients with lower respiratory tract infections. ( Hiraga, Y; Ohmichi, M, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (7.89) | 18.2507 |
| 2000's | 4 (10.53) | 29.6817 |
| 2010's | 25 (65.79) | 24.3611 |
| 2020's | 6 (15.79) | 2.80 |
| Authors | Studies |
|---|---|
| Cabrera, R | 1 |
| Fernández-Barat, L | 1 |
| Vázquez, N | 1 |
| Alcaraz-Serrano, V | 1 |
| Bueno-Freire, L | 1 |
| Amaro, R | 1 |
| López-Aladid, R | 1 |
| Oscanoa, P | 1 |
| Muñoz, L | 1 |
| Vila, J | 1 |
| Torres, A | 1 |
| Eklöf, J | 1 |
| Alispahic, IA | 1 |
| Sivapalan, P | 1 |
| Wilcke, T | 1 |
| Seersholm, N | 1 |
| Armbruster, K | 1 |
| Kjærgaard, JL | 1 |
| Saeed, MI | 1 |
| Nielsen, TL | 1 |
| Browatzki, A | 2 |
| Overgaard, RH | 1 |
| Fenlev, CS | 1 |
| Harboe, ZB | 1 |
| Andreassen, HF | 1 |
| Lapperre, TS | 1 |
| Pedersen, L | 1 |
| Johnsen, S | 1 |
| Ulrik, CS | 2 |
| Janner, J | 1 |
| Moberg, M | 1 |
| Heidemann, M | 1 |
| Weinreich, UM | 1 |
| Vijdea, R | 1 |
| Linde, H | 1 |
| Titlestad, I | 1 |
| Johansson, SL | 1 |
| Rosenvinge, FS | 1 |
| Østergaard, C | 1 |
| Ghathian, KSA | 1 |
| Gundersen, L | 1 |
| Christensen, CW | 1 |
| Bangsborg, J | 1 |
| Jensen, TT | 1 |
| Sørensen, VM | 1 |
| Ellingsgaard, T | 1 |
| Datcu, R | 1 |
| Coia, JE | 1 |
| Bodtger, U | 1 |
| Jensen, JUS | 1 |
| Tran, TT | 3 |
| Hadinoto, K | 4 |
| Chalmers, JD | 3 |
| Cipolla, D | 2 |
| Thompson, B | 2 |
| Davis, AM | 2 |
| O'Donnell, A | 2 |
| Tino, G | 1 |
| Gonda, I | 3 |
| Haworth, C | 1 |
| Froehlich, J | 2 |
| Almurshedi, AS | 1 |
| Aljunaidel, HA | 1 |
| Alquadeib, B | 1 |
| Aldosari, BN | 1 |
| Alfagih, IM | 1 |
| Almarshidy, SS | 1 |
| Eltahir, EKD | 1 |
| Mohamoud, AZ | 1 |
| Lin, L | 2 |
| Zhou, Y | 1 |
| Quan, G | 2 |
| Pan, X | 1 |
| Wu, C | 2 |
| Vallières, E | 1 |
| Tumelty, K | 1 |
| Tunney, MM | 1 |
| Hannah, R | 1 |
| Hewitt, O | 1 |
| Elborn, JS | 5 |
| Downey, DG | 1 |
| Aksamit, T | 3 |
| Bandel, TJ | 3 |
| Criollo, M | 3 |
| De Soyza, A | 5 |
| Operschall, E | 4 |
| Polverino, E | 4 |
| Roth, K | 3 |
| Winthrop, KL | 3 |
| Wilson, R | 5 |
| Cartlidge, MK | 1 |
| Hill, AT | 1 |
| Chotirmall, SH | 3 |
| McShane, PJ | 1 |
| Weers, JG | 1 |
| Tarara, TE | 1 |
| Haynes, A | 1 |
| Durbha, P | 1 |
| Miller, DP | 1 |
| Mundry, T | 1 |
| Vidaillac, C | 2 |
| Yu, H | 3 |
| Yong, VFL | 1 |
| Roizman, D | 1 |
| Chandrasekaran, R | 1 |
| Lim, AYH | 2 |
| Low, TB | 1 |
| Tan, GL | 1 |
| Abisheganaden, JA | 2 |
| Koh, MS | 1 |
| Teo, J | 2 |
| Felix, LM | 1 |
| Grundy, S | 1 |
| Milan, SJ | 1 |
| Armstrong, R | 1 |
| Harrison, H | 1 |
| Lynes, D | 1 |
| Spencer, S | 1 |
| Chorepsima, S | 1 |
| Kechagias, KS | 1 |
| Kalimeris, G | 1 |
| Triarides, NA | 1 |
| Falagas, ME | 1 |
| Haworth, CS | 1 |
| Bilton, D | 3 |
| Wanner, A | 1 |
| O'Donnell, AE | 1 |
| Grimwood, K | 1 |
| Chang, AB | 1 |
| Liu, C | 1 |
| Huang, Z | 1 |
| Wu, Q | 1 |
| Jiang, J | 1 |
| Lv, L | 1 |
| Yu, X | 1 |
| Li, G | 1 |
| Ben-Chetrit, E | 1 |
| Rothstein, N | 1 |
| Munter, G | 1 |
| Serisier, DJ | 2 |
| Thompson, PJ | 1 |
| Kolbe, J | 1 |
| Greville, HW | 1 |
| Bruinenberg, P | 1 |
| Justo, JA | 1 |
| Danziger, LH | 1 |
| Gotfried, MH | 1 |
| Gassiep, I | 1 |
| Chaudhuri, A | 1 |
| Chew, JW | 1 |
| Stass, H | 1 |
| Nagelschmitz, J | 1 |
| Kappeler, D | 1 |
| Sommerer, K | 1 |
| Kietzig, C | 1 |
| Weimann, B | 1 |
| Fjaellegaard, K | 1 |
| Sin, MD | 1 |
| Chang, B | 1 |
| Knowles, SR | 1 |
| Weber, E | 1 |
| Durdu, B | 1 |
| Durdu, Y | 1 |
| Güleç, N | 1 |
| Islim, F | 1 |
| Biçer, M | 1 |
| Welte, T | 1 |
| Greville, H | 1 |
| Alder, J | 1 |
| Reimnitz, P | 1 |
| Hampel, B | 1 |
| de la Campa, AG | 1 |
| Ferrandiz, MJ | 1 |
| Tubau, F | 1 |
| Pallarés, R | 1 |
| Manresa, F | 1 |
| Liñares, J | 1 |
| Gaur, S | 1 |
| Trayner, E | 1 |
| Aish, L | 1 |
| Weinstein, R | 1 |
| Henig, N | 1 |
| Morrissey, B | 1 |
| Gotfried, M | 1 |
| Rayner, CF | 1 |
| Tillotson, G | 1 |
| Cole, PJ | 1 |
| Chuchalin, AG | 1 |
| Novikov, IuK | 1 |
| Avdeev, SN | 1 |
| Belevskiĭ, AS | 1 |
| Begg, EJ | 1 |
| Robson, RA | 1 |
| Saunders, DA | 1 |
| Graham, GG | 1 |
| Buttimore, RC | 1 |
| Neill, AM | 1 |
| Town, GI | 1 |
| Ohmichi, M | 1 |
| Hiraga, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Targeted AntiBiotics for Chronic Pulmonary Disease: Can Targeted Antibiotic Therapy Improve the Prognosis of Pseudomonas Aeruginosa Infected Patients With Chronic Pulmonary Obstructive Disease, Non-cystic Fibrosis Bronchiectasis and Asthma? A Multicenter,[NCT03262142] | Phase 4 | 51 participants (Actual) | Interventional | 2018-01-10 | Terminated (stopped due to Slow recruitment) | ||
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Pulmaquin® in the Management of Chronic Lung Infections With Pseudomonas Aeruginosa in Subjects With Non-Cystic Fibrosis Bronchiectasis, Including 28 [NCT01515007] | Phase 3 | 278 participants (Actual) | Interventional | 2014-03-31 | Completed | ||
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Pulmaquin® in the Management of Chronic Lung Infections With Pseudomonas Aeruginosa in Patients With Non-Cystic Fibrosis Bronchiectasis, Including 28 [NCT02104245] | Phase 3 | 304 participants (Actual) | Interventional | 2014-05-28 | Completed | ||
| Efficacy and Safety of tobRamycin Inhalation Solution for Pseudomonas AeruginoSa Eradication in Bronchiectasis (ERASE): Study Protocol for a Multi-center, 2×2 Factorial Randomized, Double-blind, Placebo-controlled Trial[NCT06093191] | Phase 4 | 364 participants (Anticipated) | Interventional | 2023-09-25 | Recruiting | ||
| Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmona[NCT02106832] | Phase 3 | 521 participants (Actual) | Interventional | 2014-04-30 | Completed | ||
| Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmona[NCT01764841] | Phase 3 | 416 participants (Actual) | Interventional | 2013-05-02 | Completed | ||
| Research on the Mechanism Affecting Progression of Bronchiectasis Based on Omics Method[NCT05731427] | 150 participants (Anticipated) | Observational | 2021-02-01 | Recruiting | |||
| Effect of Roflumilast on Quality of Life, Lung Function and Mucus Properties in Patients With Non-cystic Fibrosis Bronchiectasis: a Cross-over, Unicentric, Double-blind and Placebo-controlled Study[NCT03988816] | Phase 2 | 30 participants (Anticipated) | Interventional | 2019-12-06 | Recruiting | ||
| Randomized, Placebo-controlled, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of Ciprofloxacin Inhale Compared to Placebo in Patients With Non-cystic Fibrosis Bronchiectasis[NCT00930982] | Phase 2 | 124 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| Efficacy and Safety of Inhaled Tobramycin on Bronchiectasis Colonized With Pseudomonas Aeruginosa: A Randomized, Double-blind, Parallel-group Multicenter Trial[NCT03715322] | Phase 3 | 350 participants (Anticipated) | Interventional | 2018-10-26 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
FEV1 was defined as the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration, expressed in liters at body temperature and ambient pressure saturated with water vapor (BTPS). (NCT02106832)
Timeframe: Baseline and end of treatment (Week 44/46)
| Intervention | Liter (Mean) |
|---|---|
| Ciprofloxacin DPI 28 Days on/Off (Cipro 28) | 0.038 |
| Ciprofloxacin DPI 14 Days on/Off (Cipro 14) | -0.037 |
| Placebo 28 Days on/Off (Placebo 28) | -0.038 |
| Placebo 14 Days on/Off (Placebo 14) | 0.037 |
The QoL-B was a disease-specific questionnaire developed for non-Cystic fibrosis Bronchiectasis. It covers 8 dimensions: physical functioning, role functioning, emotional functioning, social functioning, vitality, treatment burden, health perceptions, and respiratory symptoms. Each dimension was scored separately on a scale of 0 to 100, and higher scores represent better outcomes. For this outcome measure, the respiratory symptoms domain score was reported. (NCT02106832)
Timeframe: Baseline and end of treatment (Week 44/46)
| Intervention | Score on a scale (Mean) |
|---|---|
| Ciprofloxacin DPI 28 Days on/Off (Cipro 28) | 11.57 |
| Ciprofloxacin DPI 14 Days on/Off (Cipro 14) | 10.90 |
| Placebo 28 Days on/Off (Placebo 28) | 7.08 |
| Placebo 14 Days on/Off (Placebo 14) | 10.70 |
The SGRQ was a validated, disease-specific instrument that measures health-related quality of life (HRQoL) in adults with chronic obstructive pulmonary disease (COPD) and asthma and was later validated for use in bronchiectasis. The SGRQ covers 3 dimensions: symptoms, activity and impact on daily life. To determine the outcome, a score ranging from 1 to 100 was calculated for each individual domain and for the total score, and smaller scores indicate better health status. For this outcome measure, the symptoms component score was reported. (NCT02106832)
Timeframe: Baseline and end of treatment (Week 44/46)
| Intervention | Score on a scale (Mean) |
|---|---|
| Ciprofloxacin DPI 28 Days on/Off (Cipro 28) | -8.92 |
| Ciprofloxacin DPI 14 Days on/Off (Cipro 14) | -9.02 |
| Placebo 28 Days on/Off (Placebo 28) | -2.91 |
| Placebo 14 Days on/Off (Placebo 14) | -11.50 |
Time to first exacerbation was defined as the time from randomization until the visit at which the first qualifying exacerbation is recorded by the investigator. Exacerbation events are defined as exacerbations with systemic antibiotic use and presence of fever or malaise / fatigue and worsening of at least three signs/symptoms. (NCT02106832)
Timeframe: Up to Week 48
| Intervention | Days (Median) |
|---|---|
| Ciprofloxacin DPI 14 Days on/Off (Cipro 14) | NA |
| Pooled Placebo | NA |
Time to first exacerbation was defined as the time from randomization until the visit at which the first qualifying exacerbation is recorded by the investigator. Exacerbation events are defined as exacerbations with systemic antibiotic use and presence of fever or malaise / fatigue and worsening of at least three signs/symptoms. (NCT02106832)
Timeframe: Up to Week 48
| Intervention | Days (Median) |
|---|---|
| Ciprofloxacin DPI 28 Days on/Off (Cipro 28) | NA |
| Pooled Placebo | NA |
For this outcome measure, exacerbation events were defined as exacerbations with systemic antibiotic use and worsening of at least one sign/symptom over 48 weeks. (NCT02106832)
Timeframe: Up to Week 48
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| Number of exacerbations: 0 | Number of exacerbations: 1 | Number of exacerbations: 2 | Number of exacerbations: 3 | Number of exacerbations: 4 | Number of exacerbations: 5 | |
| Ciprofloxacin DPI 14 Days on/Off (Cipro 14) | 96 | 46 | 26 | 4 | 3 | 1 |
| Ciprofloxacin DPI 28 Days on/Off (Cipro 28) | 102 | 51 | 14 | 3 | 1 | 0 |
| Pooled Placebo | 90 | 45 | 22 | 11 | 4 | 2 |
For this outcome measure, exacerbation events were defined as exacerbations with systemic antibiotic use and presence of fever or malaise / fatigue and worsening of at least three signs/symptoms over 48 weeks. (NCT02106832)
Timeframe: Up to Week 48
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| Number of exacerbations: 0 | Number of exacerbations: 1 | Number of exacerbations: 2 | Number of exacerbations: 3 | Number of exacerbations: 4 | Number of exacerbations: 5 | |
| Ciprofloxacin DPI 14 Days on/Off (Cipro 14) | 108 | 40 | 23 | 4 | 1 | 0 |
| Ciprofloxacin DPI 28 Days on/Off (Cipro 28) | 115 | 46 | 8 | 2 | 0 | 0 |
| Pooled Placebo | 101 | 41 | 19 | 10 | 2 | 1 |
New pathogens were any of the pre-specified organisms not cultured before start of study medication. There was no imputation for participants who discontinued the study prematurely. (NCT02106832)
Timeframe: End of treatment (Week 44/46)
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| No | Yes | |
| Ciprofloxacin DPI 14 Days on/Off (Cipro 14) | 67.6 | 4.0 |
| Ciprofloxacin DPI 28 Days on/Off (Cipro 28) | 62.6 | 4.1 |
| Pooled Placebo | 61.5 | 10.3 |
Pathogen eradication was defined as a negative culture result for all pre-specified pathogens at end of treatment (week 44 or 46 depending on treatment regimen) that were present in the participant at baseline. There was no imputation for participants who discontinued the study prematurely. (NCT02106832)
Timeframe: End of treatment (Week 44/46)
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| No | Yes | |
| Ciprofloxacin DPI 14 Days on/Off (Cipro 14) | 35.8 | 35.8 |
| Ciprofloxacin DPI 28 Days on/Off (Cipro 28) | 35.1 | 31.6 |
| Pooled Placebo | 40.2 | 31.6 |
FEV1 was defined as the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration, expressed in liters at body temperature and ambient pressure saturated with water vapor (BTPS). (NCT01764841)
Timeframe: Baseline and end of treatment (Week 44/46)
| Intervention | Liter (Mean) |
|---|---|
| Ciprofloxacin DPI 28 Days on/Off (Cipro 28) | -0.012 |
| Ciprofloxacin DPI 14 Days on/Off (Cipro 14) | -0.026 |
| Placebo 28 Days on/Off (Placebo 28) | 0.024 |
| Placebo 14 Days on/Off (Placebo 14) | 0.022 |
The QoL-B was a disease-specific questionnaire developed for non-Cystic fibrosis Bronchiectasis. It covers 8 dimensions: physical functioning, role functioning, emotional functioning, social functioning, vitality, treatment burden, health perceptions, and respiratory symptoms. Each dimension was scored separately on a scale of 0 to 100, and higher scores represent better outcomes. For this outcome measure, the respiratory symptoms domain score was reported. (NCT01764841)
Timeframe: Baseline and end of treatment (Week 44/46)
| Intervention | Score on a scale (Mean) |
|---|---|
| Ciprofloxacin DPI 28 Days on/Off (Cipro 28) | 7.70 |
| Ciprofloxacin DPI 14 Days on/Off (Cipro 14) | 6.72 |
| Placebo 28 Days on/Off (Placebo 28) | 8.22 |
| Placebo 14 Days on/Off (Placebo 14) | 4.45 |
The SGRQ was a validated, disease-specific instrument that measures health-related quality of life (HRQoL) in adults with chronic obstructive pulmonary disease (COPD) and asthma and was later validated for use in bronchiectasis. The SGRQ covers 3 dimensions: symptoms, activity and impact on daily life. To determine the outcome, a score ranging from 1 to 100 was calculated for each individual domain and for the total score, and smaller scores indicate better health status. For this outcome measure, the symptoms component score was reported. (NCT01764841)
Timeframe: Baseline and end of treatment (Week 44/46)
| Intervention | Score on a scale (Mean) |
|---|---|
| Ciprofloxacin DPI 28 Days on/Off (Cipro 28) | -8.17 |
| Ciprofloxacin DPI 14 Days on/Off (Cipro 14) | -7.20 |
| Placebo 28 Days on/Off (Placebo 28) | -4.23 |
| Placebo 14 Days on/Off (Placebo 14) | 2.78 |
Time to first exacerbation was defined as the time from randomization until the visit at which the first qualifying exacerbation is recorded by the investigator. Exacerbation events are defined as exacerbations with systemic antibiotic use and presence of fever or malaise / fatigue and worsening of at least three signs/symptoms. (NCT01764841)
Timeframe: Up to Week 48
| Intervention | Days (Median) |
|---|---|
| Ciprofloxacin DPI 28 Days on/Off (Cipro 28) | 336 |
| Ciprofloxacin DPI 14 Days on/Off (Cipro 14) | NA |
| Pooled Placebo | 186 |
For this outcome measure, exacerbation events were defined as exacerbations with systemic antibiotic use and worsening of at least one sign/symptom over 48 weeks. (NCT01764841)
Timeframe: Up to Week 48
| Intervention | Participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Number of exacerbations: 0 | Number of exacerbations: 1 | Number of exacerbations: 2 | Number of exacerbations: 3 | Number of exacerbations: 4 | Number of exacerbations: 5 | Number of exacerbations: 6 | |
| Ciprofloxacin DPI 14 Days on/Off (Cipro 14) | 68 | 42 | 15 | 5 | 2 | 3 | 2 |
| Ciprofloxacin DPI 28 Days on/Off (Cipro 28) | 58 | 47 | 12 | 14 | 4 | 4 | 2 |
| Pooled Placebo | 46 | 43 | 31 | 11 | 5 | 2 | 0 |
For this outcome measure, exacerbation events were defined as exacerbations with systemic antibiotic use and presence of fever or malaise / fatigue and worsening of at least three signs/symptoms over 48 weeks. (NCT01764841)
Timeframe: Up to Week 48
| Intervention | Participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Number of exacerbations: 0 | Number of exacerbations: 1 | Number of exacerbations: 2 | Number of exacerbations: 3 | Number of exacerbations: 4 | Number of exacerbations: 5 | Number of exacerbations: 6 | Number of exacerbations: 7 | |
| Ciprofloxacin DPI 14 Days on/Off (Cipro 14) | 72 | 38 | 13 | 8 | 3 | 2 | 0 | 1 |
| Ciprofloxacin DPI 28 Days on/Off (Cipro 28) | 66 | 44 | 12 | 12 | 3 | 1 | 0 | 3 |
| Pooled Placebo | 44 | 58 | 19 | 7 | 8 | 0 | 1 | 1 |
New pathogens were any of the pre-specified organisms not cultured before start of study medication. There was no imputation for participants who discontinued the study prematurely. (NCT01764841)
Timeframe: End of treatment (Week 44/46)
| Intervention | Percentage of Participants (Number) | |
|---|---|---|
| No | Yes | |
| Ciprofloxacin DPI 14 Days on/Off (Cipro 14) | 49.6 | 5.1 |
| Ciprofloxacin DPI 28 Days on/Off (Cipro 28) | 60.3 | 3.5 |
| Pooled Placebo | 42.8 | 8.0 |
Pathogen eradication was defined as a negative culture result for all pre-specified pathogens at end of treatment (week 44 or 46 depending on treatment regimen) that were present in the participant at baseline. There was no imputation for participants who discontinued the study prematurely. (NCT01764841)
Timeframe: End of treatment (Week 44/46)
| Intervention | Percentage of Participants (Number) | |
|---|---|---|
| No | Yes | |
| Ciprofloxacin DPI 14 Days on/Off (Cipro 14) | 26.3 | 28.5 |
| Ciprofloxacin DPI 28 Days on/Off (Cipro 28) | 39.0 | 24.1 |
| Pooled Placebo | 33.3 | 16.7 |
Total bacterial load was determined in sputum collected before the inhalation of study drug. Sputum samples were either provided by the participant during the respective study visit, or participants had to bring a sputum sample that had been produced within the 4 hours prior to the visit. Induced sputum samples could be collected if the participant was unable to produce a spontaneously expectorated sputum sample of > 2 mL. Imputation method: last observation carried forward (LOCF). CFU: colony forming units, log10: decadic logarithm (NCT00930982)
Timeframe: Baseline and 29 days
| Intervention | log10 of CFU per gram sputum (Mean) |
|---|---|
| Ciprofloxacin Inhale (BAYQ3939) | -2.94 |
| Placebo | -0.32 |
Acute exacerbation was defined according to the joint American Thoracic Society/European Respiratory Society criteria. For detailed information with regard to this definition of acute exacerbation, please refer to the detailed description in the protocol section. The time to an acute exacerbation with antibiotic intervention was determined. (NCT00930982)
Timeframe: Up to end of study (planned at Day 84)
| Intervention | Days (Median) |
|---|---|
| Ciprofloxacin Inhale (BAYQ3939) | NA |
| Placebo | NA |
Participants were asked to start 24-hour sputum collection samples 24 hours before coming for the respective study visit. Sputum color was assessed as either 'clear', or as 'yellow', 'green' or 'rust', or an assessment of 'no sputum' was made. (NCT00930982)
Timeframe: Up to end of study (planned at Day 84)
| Intervention | Percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Day 1 | Day 8 | Day 29 | Day 42 | Day 56 | Day 84 | |
| Ciprofloxacin Inhale (BAYQ3939) | 91.7 | 73.2 | 75.5 | 72.8 | 75.0 | 66.6 |
| Placebo | 88.9 | 94.9 | 82.7 | 88.4 | 86.5 | 72.8 |
Participants were asked to start 24-hour sputum collection samples 24 hours before coming for the respective study visit. The volume of the completed sample was determined. (NCT00930982)
Timeframe: Up to end of study (planned at Day 84)
| Intervention | mL (Mean) | |||||
|---|---|---|---|---|---|---|
| Day 1 | Day 8 | Day 29 | Day 42 | Day 56 | Day 84 | |
| Ciprofloxacin Inhale (BAYQ3939) | 24.9 | 18.9 | 20.5 | 21.1 | 19.6 | 23.6 |
| Placebo | 30.2 | 30.0 | 27.3 | 22.8 | 22.0 | 25.9 |
Absolute neutrophil count (ANC) was determined from safety blood samples. Missing or invalid values were replaced with the last valid value available. (NCT00930982)
Timeframe: Baseline and up to Day 42
| Intervention | giga/L (Mean) | ||
|---|---|---|---|
| Day 8 | Day 29 | Day 42 | |
| Ciprofloxacin Inhale (BAYQ3939) | -0.35 | -0.36 | -0.28 |
| Placebo | -0.03 | 0.59 | 0.24 |
Pulmonary function testing (spirometry) was conducted in accordance with American Thoracic Society standards. FEV1 was defined as the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration, expressed in liters at body temperature and ambient pressure saturated with water vapor (BTPS). Imputation method: last observation carried forward (LOCF). (NCT00930982)
Timeframe: Baseline and up to end of study (planned at Day 84)
| Intervention | Percent of predicted FEV1 (Mean) | ||||
|---|---|---|---|---|---|
| Day 8 | Day 29 | Day 42 | Day 56 | Day 84 | |
| Ciprofloxacin Inhale (BAYQ3939) | -0.67 | -0.53 | 1.19 | 0.81 | 0.70 |
| Placebo | -0.14 | -0.22 | -0.26 | -0.24 | -0.50 |
Pulmonary function testing (spirometry) was conducted in accordance with American Thoracic Society standards. FVC was defined as the maximal volume of air exhaled with maximally forced effort from a maximal inspiration, i.e. vital capacity performed with a maximally forced expiratory effort expressed in liters at BTPS. Imputation method: last observation carried forward (LOCF). (NCT00930982)
Timeframe: Baseline and up to end of study (planned at Day 84)
| Intervention | Percent of predicted FVC (Mean) | ||||
|---|---|---|---|---|---|
| Day 8 | Day 29 | Day 42 | Day 56 | Day 84 | |
| Ciprofloxacin Inhale (BAYQ3939) | -0.33 | -0.76 | 0.92 | 0.36 | -0.01 |
| Placebo | 0.04 | -1.05 | -1.09 | -1.16 | -1.99 |
High sensitive C-reactive protein (hsCRP) was determined from safety blood samples. Missing or invalid values were replaced with the last valid value available. (NCT00930982)
Timeframe: Baseline and up to Day 42
| Intervention | mg/L (Median) | ||
|---|---|---|---|
| Day 8 | Day 29 | Day 42 | |
| Ciprofloxacin Inhale (BAYQ3939) | -0.43 | 0 | -0.16 |
| Placebo | -0.19 | 0 | 0.12 |
Total bacterial load was determined in sputum collected before the inhalation of study drug. Sputum samples were either provided by the participant during the respective study visit, or participants had to bring a sputum sample that had been produced within the 4 hours prior to the visit. Induced sputum samples could be collected if the participant was unable to produce a spontaneously expectorated sputum sample of > 2 mL on Day 8. Imputation method: last observation carried forward (LOCF). CFU: colony forming units, log10: decadic logarithm (NCT00930982)
Timeframe: Baseline and up to end of study (planned at Day 84)
| Intervention | log10 of CFU per gram sputum (Mean) | |||
|---|---|---|---|---|
| Day 8 | Day 42 | Day 56 | Day 84 | |
| Ciprofloxacin Inhale (BAYQ3939) | -2.87 | -1.86 | -1.86 | -1.37 |
| Placebo | -0.20 | -0.31 | -0.21 | -0.24 |
Participants completed the Chronic Respiratory Questionnaire - Self Administered Standardized (CRQ-SAS). They were assured that all data would be treated confidentially and that the answers would not have any influence on study drug treatment. Participants completed the questionnaires on their own in a quiet area, without discussing them with study staff or accompanying persons (e.g. friends or relatives) and before being seen by the clinician. The score ranges between 1 and 7, 1 being the worst possible score. (NCT00930982)
Timeframe: Up to end of study (planned at Day 84)
| Intervention | Total score on a scale (Mean) | |||
|---|---|---|---|---|
| Day 1 | Day 29 | Day 56 | Day 84 | |
| Ciprofloxacin Inhale (BAYQ3939) | 4.88 | 4.99 | 4.94 | 5.01 |
| Placebo | 4.96 | 4.93 | 4.91 | 4.99 |
Participants completed the Saint George's Respiratory Questionnaire (SGRQ). They were assured that all data would be treated confidentially and that the answers would not have any influence on study drug treatment. Participants completed the questionnaires on their own in a quiet area, without discussing them with study staff or accompanying persons (e.g. friends or relatives) and before being seen by the clinician. The score ranges from 0 to 100 with 100 being the worst possible score. (NCT00930982)
Timeframe: Up to end of study (planned at Day 84)
| Intervention | Scores on a scale (Mean) | |||
|---|---|---|---|---|
| Day 1 | Day 29 | Day 56 | Day 84 | |
| Ciprofloxacin Inhale (BAYQ3939) | 43.8 | 41.5 | 40.6 | 40.6 |
| Placebo | 44.7 | 44.8 | 44.1 | 41.6 |
The emergence of new potential respiratory pathogens was evaluated using microbiological analysis. Evaluated was the cumulative number of participants with first appearance of new potential respiratory antigens at each time point. In some cases, participants attended the end of study visit later than Day 84 (up to Day 88). (NCT00930982)
Timeframe: Up to end of study (planned at Day 84)
| Intervention | Cumulative participants (Number) | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 4 | Day 5 | Day 7 | Day 8 | Day 9 | Day 10 | Day 14 | Day 15 | Day 28 | Day 29 | Day 30 | Day 36 | Day 39 | Day 42 | Day 43 | Day 44 | Day 45 | Day 57 | Day 58 | Day 59 | Day 78 | Day 83 | Day 84 | Day 85 | Day 86 | Day 88 | |
| Ciprofloxacin Inhale (BAYQ3939) | 1 | 1 | 2 | 7 | 7 | 7 | 7 | 7 | 7 | 12 | 14 | 15 | 16 | 18 | 21 | 25 | 26 | 29 | 29 | 30 | 31 | 32 | 33 | 38 | 41 | 43 |
| Placebo | 0 | 2 | 2 | 8 | 10 | 11 | 12 | 13 | 14 | 24 | 30 | 30 | 31 | 33 | 38 | 40 | 41 | 45 | 46 | 47 | 47 | 47 | 47 | 53 | 54 | 54 |
The emergence of resistance (at least two-fold increase of Minimal inhibitory concentration, MIC, vs. baseline values) probably or possibly related to study medication among baseline pathogens was evaluated using microbiological analysis. (NCT00930982)
Timeframe: Up to end of study (planned at Day 84)
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Emergence (>= 2* increase of MIC) | Sustained (>= 2* increase of MIC until end) | Transient (Increase in MIC with normalization) | Insufficient follow up | |
| Ciprofloxacin Inhale (BAYQ3939) | 7 | 1 | 5 | 1 |
| Placebo | 1 | 0 | 1 | 0 |
Microbiological response was defined as reduction in bacterial load or eradication (measured as the percentage of participants with positive culture). Missing values were not imputed. (NCT00930982)
Timeframe: Up to end of study (planned at Day 84)
| Intervention | Percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Day 1 | Day 8 | Day 29 | Day 42 | Day 56 | Day 84 | |
| Ciprofloxacin Inhale (BAYQ3939) | 100.0 | 52.4 | 65.0 | 83.3 | 87.1 | 85.2 |
| Placebo | 100.0 | 88.2 | 91.8 | 86.8 | 96.4 | 92.0 |
Microbiological response was defined as reduction in bacterial load or eradication (measured as the number of participants with positive culture). Missing values were not imputed. Pathogens analyzed: Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Proteus mirabilis, Serratia marcescens, Pseudomonas aeruginosa, mucoid, Pseudomonas aeruginosa, non mucoid, Stenotrophomonas maltophilia, Achromobacter xylosoxydans, Moraxella catarrhalis, Haemophilus influenzae (NCT00930982)
Timeframe: Up to end of study (planned at Day 84)
| Intervention | Participants (Number) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S. aureus Day 1 | S. aureus Day 8 | S. aureus Day 29 | S. aureus Day 42 | S. aureus Day 56 | S. aureus Day 84 | S. pneumoniae Day 1 | S. pneumoniae Day 8 | S. pneumoniae Day 29 | S. pneumoniae Day 42 | S. pneumoniae Day 56 | S. pneumoniae Day 84 | E. coli Day 1 | E. coli Day 8 | E. coli Day 29 | E. coli Day 42 | E. coli Day 56 | E. coli Day 84 | K. pneumoniae Day 1 | K. pneumoniae Day 8 | K. pneumoniae Day 29 | K. pneumoniae Day 42 | K. pneumoniae Day 56 | K. pneumoniae Day 84 | K. oxytoca Day 1 | K. oxytoca Day 8 | K. oxytoca Day 29 | K. oxytoca Day 42 | K. oxytoca Day 56 | K. oxytoca Day 84 | P. mirabilis Day 1 | P. mirabilis Day 8 | P. mirabilis Day 29 | P. mirabilis Day 42 | P. mirabilis Day 56 | P. mirabilis Day 84 | S. marcescens Day 1 | S. marcescens Day 8 | S. marcescens Day 29 | S. marcescens Day 42 | S. marcescens Day 56 | S. marcescens Day 84 | P. aeruginosa, mucoid Day 1 | P. aeruginosa, mucoid Day 8 | P. aeruginosa, mucoid Day 29 | P. aeruginosa, mucoid Day 42 | P. aeruginosa, mucoid Day 56 | P. aeruginosa, mucoid Day 84 | P. aeruginosa, non mucoid Day 1 | P. aeruginosa, non mucoid Day 8 | P. aeruginosa, non mucoid Day 29 | P. aeruginosa, non mucoid Day 42 | P. aeruginosa, non mucoid Day 56 | P. aeruginosa, non mucoid Day 84 | S. maltophilia Day 1 | S. maltophilia Day 8 | S. maltophilia Day 29 | S. maltophilia Day 42 | S. maltophilia Day 56 | S. maltophilia Day 84 | A. xylosoxydans Day 1 | A. xylosoxydans Day 8 | A. xylosoxydans Day 29 | A. xylosoxydans Day 42 | A. xylosoxydans Day 56 | A. xylosoxydans Day 84 | M. catarrhalis Day 1 | M. catarrhalis Day 8 | M. catarrhalis Day 29 | M. catarrhalis Day 42 | M. catarrhalis Day 56 | M. catarrhalis Day 84 | H. influenzae Day 1 | H. influenzae Day 8 | H. influenzae Day 29 | H. influenzae Day 42 | H. influenzae Day 56 | H. influenzae Day 84 | |
| Ciprofloxacin Inhale (BAYQ3939) | 8 | 4 | 5 | 6 | 8 | 5 | 7 | 2 | 0 | 3 | 1 | 1 | 2 | 2 | 2 | 0 | 1 | 1 | 5 | 0 | 0 | 0 | 1 | 3 | 3 | 0 | 0 | 0 | 0 | 1 | 3 | 0 | 0 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 2 | 12 | 7 | 9 | 9 | 6 | 4 | 20 | 6 | 10 | 12 | 10 | 13 | 2 | 0 | 2 | 2 | 4 | 1 | 2 | 2 | 2 | 2 | 1 | 0 | 5 | 0 | 0 | 1 | 1 | 1 | 14 | 1 | 1 | 1 | 3 | 4 |
| Placebo | 17 | 7 | 10 | 9 | 5 | 5 | 2 | 4 | 4 | 1 | 2 | 1 | 2 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 2 | 1 | 2 | 1 | 1 | 1 | 4 | 3 | 1 | 3 | 2 | 2 | 3 | 2 | 3 | 3 | 2 | 0 | 16 | 15 | 16 | 12 | 6 | 5 | 19 | 17 | 14 | 12 | 9 | 6 | 3 | 3 | 3 | 1 | 3 | 1 | 3 | 2 | 1 | 0 | 1 | 2 | 3 | 3 | 6 | 2 | 2 | 2 | 16 | 12 | 11 | 7 | 8 | 8 |
7 reviews available for ciprofloxacin and Bronchiectasis
| Article | Year |
|---|---|
Inhaled or nebulised ciprofloxacin for the maintenance treatment of bronchiectasis.
Topics: Administration, Inhalation; Animals; Anti-Bacterial Agents; Bronchiectasis; Ciprofloxacin; Drug Resi | 2017 |
Ciprofloxacin Dry Powder for Inhalation (ciprofloxacin DPI): Technical design and features of an efficient drug-device combination.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Bronchiectasis; Ciprofloxacin; Dry Powder Inhaler | 2018 |
Dual antibiotics for bronchiectasis.
Topics: Adult; Anti-Bacterial Agents; Bronchiectasis; Ciprofloxacin; Gentamicins; Humans; Middle Aged; Pseud | 2018 |
Spotlight on inhaled ciprofloxacin and its potential in the treatment of non-cystic fibrosis bronchiectasis.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bronc | 2018 |
Efficacy of inhaled ciprofloxacin in the management of non-cystic fibrosis bronchiectasis.
Topics: Administration, Inhalation; Animals; Anti-Bacterial Agents; Bronchiectasis; Chemistry, Pharmaceutica | 2013 |
Antibiotic therapy for stable non-CF bronchiectasis in adults - A systematic review.
Topics: Aminoglycosides; Anti-Bacterial Agents; Aztreonam; Bronchiectasis; Ciprofloxacin; Colistin; Disease | 2017 |
Inhaled antibiotics for lower respiratory tract infections: focus on ciprofloxacin.
Topics: Administration, Inhalation; Animals; Anti-Bacterial Agents; Bronchiectasis; Ciprofloxacin; Clinical | 2012 |
12 trials available for ciprofloxacin and Bronchiectasis
| Article | Year |
|---|---|
Targeted AntiBiotics for Chronic pulmonary diseases (TARGET ABC): can targeted antibiotic therapy improve the prognosis of Pseudomonas aeruginosa-infected patients with chronic pulmonary obstructive disease, non-cystic fibrosis bronchiectasis, and asthma?
Topics: Anti-Bacterial Agents; Asthma; beta-Lactams; Bronchiectasis; Ciprofloxacin; Fibrosis; Humans; Predni | 2022 |
The RESPIRE trials: Two phase III, randomized, multicentre, placebo-controlled trials of Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) in non-cystic fibrosis bronchiectasis.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Bronchiectasis; Ciprofloxacin; Clinical Protocols | 2017 |
The RESPIRE trials: Two phase III, randomized, multicentre, placebo-controlled trials of Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) in non-cystic fibrosis bronchiectasis.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Bronchiectasis; Ciprofloxacin; Clinical Protocols | 2017 |
The RESPIRE trials: Two phase III, randomized, multicentre, placebo-controlled trials of Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) in non-cystic fibrosis bronchiectasis.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Bronchiectasis; Ciprofloxacin; Clinical Protocols | 2017 |
The RESPIRE trials: Two phase III, randomized, multicentre, placebo-controlled trials of Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) in non-cystic fibrosis bronchiectasis.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Bronchiectasis; Ciprofloxacin; Clinical Protocols | 2017 |
RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis.
Topics: Administration, Inhalation; Aged; Anti-Bacterial Agents; Bronchiectasis; Ciprofloxacin; Double-Blind | 2018 |
RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis.
Topics: Administration, Inhalation; Aged; Anti-Bacterial Agents; Bronchiectasis; Ciprofloxacin; Double-Blind | 2018 |
RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis.
Topics: Administration, Inhalation; Aged; Anti-Bacterial Agents; Bronchiectasis; Ciprofloxacin; Double-Blind | 2018 |
RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis.
Topics: Administration, Inhalation; Aged; Anti-Bacterial Agents; Bronchiectasis; Ciprofloxacin; Double-Blind | 2018 |
RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis.
Topics: Administration, Inhalation; Aged; Anti-Bacterial Agents; Bronchiectasis; Ciprofloxacin; Double-Blind | 2018 |
RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis.
Topics: Administration, Inhalation; Aged; Anti-Bacterial Agents; Bronchiectasis; Ciprofloxacin; Double-Blind | 2018 |
RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis.
Topics: Administration, Inhalation; Aged; Anti-Bacterial Agents; Bronchiectasis; Ciprofloxacin; Double-Blind | 2018 |
RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis.
Topics: Administration, Inhalation; Aged; Anti-Bacterial Agents; Bronchiectasis; Ciprofloxacin; Double-Blind | 2018 |
Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Bronchiectasis; Ciprofloxacin; Double-Blind Metho | 2019 |
Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Bronchiectasis; Ciprofloxacin; Double-Blind Metho | 2019 |
Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Bronchiectasis; Ciprofloxacin; Double-Blind Metho | 2019 |
Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Bronchiectasis; Ciprofloxacin; Double-Blind Metho | 2019 |
Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial.
Topics: Administration, Inhalation; Aged; Anti-Bacterial Agents; Bronchiectasis; Ciprofloxacin; Delayed-Acti | 2013 |
Ciprofloxacin Dry Powder for Inhalation in Patients with Non-Cystic Fibrosis Bronchiectasis or Chronic Obstructive Pulmonary Disease, and in Healthy Volunteers.
Topics: Administration, Inhalation; Adult; Aged; Anti-Bacterial Agents; Biological Availability; Bronchiecta | 2017 |
Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study.
Topics: Administration, Inhalation; Aged; Anti-Bacterial Agents; Bacterial Load; Bronchiectasis; Ciprofloxac | 2013 |
Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis.
Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-B | 2006 |
Efficacy and safety of long-term ciprofloxacin in the management of severe bronchiectasis.
Topics: Adult; Aged; Bronchiectasis; Ciprofloxacin; Dose-Response Relationship, Drug; Drug Administration Sc | 1994 |
[Effectiveness of ciprofloxacin in the treatment of hospital infections of the lower respiratory tract].
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Infective Agents; Bronchiectasis; Bronchitis; Ch | 1997 |
The pharmacokinetics of oral fleroxacin and ciprofloxacin in plasma and sputum during acute and chronic dosing.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Area Under Curve; Bronchiectasis; Bronchitis; | 2000 |
19 other studies available for ciprofloxacin and Bronchiectasis
| Article | Year |
|---|---|
Resistance mechanisms and molecular epidemiology of Pseudomonas aeruginosa strains from patients with bronchiectasis.
Topics: Anti-Bacterial Agents; beta-Lactamases; Bronchiectasis; Ceftazidime; Ciprofloxacin; Humans; Microbia | 2022 |
Ternary nanoparticle complex of antibiotic, polyelectrolyte, and mucolytic enzyme as a potential antibiotic delivery system in bronchiectasis therapy.
Topics: Anti-Bacterial Agents; Biofilms; Bronchiectasis; Ciprofloxacin; Dextran Sulfate; Drug Delivery Syste | 2020 |
Changes in respiratory symptoms during 48-week treatment with ARD-3150 (inhaled liposomal ciprofloxacin) in bronchiectasis: results from the ORBIT-3 and -4 studies.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Bronchiectasis; Ciprofloxacin; Humans; Pseudomona | 2020 |
Changes in respiratory symptoms during 48-week treatment with ARD-3150 (inhaled liposomal ciprofloxacin) in bronchiectasis: results from the ORBIT-3 and -4 studies.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Bronchiectasis; Ciprofloxacin; Humans; Pseudomona | 2020 |
Changes in respiratory symptoms during 48-week treatment with ARD-3150 (inhaled liposomal ciprofloxacin) in bronchiectasis: results from the ORBIT-3 and -4 studies.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Bronchiectasis; Ciprofloxacin; Humans; Pseudomona | 2020 |
Changes in respiratory symptoms during 48-week treatment with ARD-3150 (inhaled liposomal ciprofloxacin) in bronchiectasis: results from the ORBIT-3 and -4 studies.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Bronchiectasis; Ciprofloxacin; Humans; Pseudomona | 2020 |
Development of Inhalable Nanostructured Lipid Carriers for Ciprofloxacin for Noncystic Fibrosis Bronchiectasis Treatment.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Bronchiectasis; Chitosan; Ciprofloxacin; Drug Car | 2021 |
The rough inhalable ciprofloxacin hydrochloride microparticles based on silk fibroin for non-cystic fibrosis bronchiectasis therapy with good biocompatibility.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Bronchiectasis; Ciprofloxacin; Dry Powder Inhaler | 2021 |
Efficacy of
Topics: Administration, Intravenous; Administration, Oral; Aged; Anti-Bacterial Agents; Bronchiectasis; Cipr | 2017 |
RESPIRE: breathing new life into bronchiectasis.
Topics: Administration, Inhalation; Bronchiectasis; Ciprofloxacin; Humans; Quality of Life; Respiration | 2018 |
A new therapeutic avenue for bronchiectasis: Dry powder inhaler of ciprofloxacin nanoplex exhibits superior ex vivo mucus permeability and antibacterial efficacy to its native ciprofloxacin counterpart.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Bronchiectasis; Case-Control Studies; Chemistry, | 2018 |
A new dawn: inhaled antibiotics for patients with bronchiectasis.
Topics: Anti-Bacterial Agents; Bronchiectasis; Ciprofloxacin; Fibrosis; Humans; Pseudomonas aeruginosa | 2019 |
Novel Inhalable Ciprofloxacin Dry Powders for Bronchiectasis Therapy: Mannitol-Silk Fibroin Binary Microparticles with High-Payload and Improved Aerosolized Properties.
Topics: Administration, Inhalation; Aerosols; Anti-Bacterial Agents; Bronchiectasis; Ciprofloxacin; Dry Powd | 2019 |
An evaluation of inhaled antibiotic liposome versus antibiotic nanoplex in controlling infection in bronchiectasis.
Topics: A549 Cells; Administration, Inhalation; Adult; Anti-Bacterial Agents; Bronchiectasis; Cell Line, Tum | 2019 |
Ciprofloxacin-induced psychosis.
Topics: Bronchiectasis; Ciprofloxacin; Humans; Lung; Male; Middle Aged; Psychoses, Substance-Induced; Pulmon | 2013 |
Is there a role for antimicrobial stewardship in bronchiectasis?
Topics: Administration, Intravenous; Administration, Oral; Anti-Bacterial Agents; Bronchiectasis; Ciprofloxa | 2015 |
Dry powder inhaler formulation of high-payload antibiotic nanoparticle complex intended for bronchiectasis therapy: Spray drying versus spray freeze drying preparation.
Topics: Aerosols; Anti-Bacterial Agents; Bronchiectasis; Chemistry, Pharmaceutical; Ciprofloxacin; Drug Comp | 2016 |
Immediate hypersensitivity to moxifloxacin with tolerance to ciprofloxacin: report of three cases and review of the literature.
Topics: Adult; Anti-Bacterial Agents; Aza Compounds; Bronchiectasis; Ciprofloxacin; Drug Eruptions; Drug Hyp | 2010 |
[A rare cause of pneumonia: Shewanella putrefaciens].
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Bronchiectasis; Ceftazidime; Ceftriaxone; Cipro | 2012 |
Genetic characterization of fluoroquinolone-resistant Streptococcus pneumoniae strains isolated during ciprofloxacin therapy from a patient with bronchiectasis.
Topics: Anti-Infective Agents; Bronchiectasis; Ciprofloxacin; Drug Resistance, Bacterial; Humans; Male; Midd | 2003 |
Bronchus-associated lymphoid tissue lymphoma arising in a patient with bronchiectasis and chronic Mycobacterium avium infection.
Topics: Aged; Anti-Infective Agents; Bronchial Neoplasms; Bronchiectasis; Chronic Disease; Ciprofloxacin; Cl | 2004 |
The efficacy, safety and pharmacokinetics of intravenous ciprofloxacin in patients with lower respiratory tract infections.
Topics: Adult; Aged; Anti-Infective Agents; Bronchiectasis; Bronchiolitis; Ciprofloxacin; Female; Humans; In | 1999 |